Upload
Featured Recent Articles Topics Login Upload

Search Results for 'sof genotype'

sof genotype published presentations and documents on DocSlides.

C-SWIFT Study: elbasvir/grazoprevir + SOF
C-SWIFT Study: elbasvir/grazoprevir + SOF
by myesha-ticknor
in genotypes 1 or 3, with or without cirrhosis. &...
C-SWIFT Study: elbasvir/grazoprevir + SOF
C-SWIFT Study: elbasvir/grazoprevir + SOF
by pamella-moone
in genotypes 1 or 3, with or without cirrhosis. &...
SOF/VEL/VOX
SOF/VEL/VOX
by celsa-spraggs
400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL ...
SOF/VEL
SOF/VEL
by lois-ondreau
400/100 mg . qd. N = 500. N = 100. W12. Placebo. ...
SMV 150 mg QD SOF 400 mg QD
SMV 150 mg QD SOF 400 mg QD
by alida-meadow
Randomisation. 1 : 1. 18-70 years. HCV genotype 1...
SMV + DCV + SOF Open label
SMV + DCV + SOF Open label
by summer
≥ 18 years. Chronic HCV infection. Genotype 1 or...
SOF/VEL/VOX
SOF/VEL/VOX
by pamella-moone
400/100/100 mg QD. N = 263. N = 152. W12. Placebo...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
LDV/SOF
LDV/SOF
by conchita-marotz
Open-label. Chronic HCV infection. Genotype 1 . F...
SOF/VEL + RBV
SOF/VEL + RBV
by celsa-spraggs
N = 69. >. 18 years. Failure to SOF/VEL . or ...
SOF/VEL
SOF/VEL
by trish-goza
400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV...
LDV/SOF 90/400 mg
LDV/SOF 90/400 mg
by aaron
qd. Non-randomised. Open-label. N =. 21. W12. SV...
Hepatitis C Drug Pipeline
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...
SMV 150 mg
SMV 150 mg
by faustina-dinatale
qd. + SOF 400 mg . qd. N = 40. W12. 18-70 years....
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
SOF/VEL + GS-9857 N = 33
SOF/VEL + GS-9857 N = 33
by taylor291
>. 18 years. Genotype 2, 3, 4, 5 or 6. HCV RNA...
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:
by kittie-lecroy
Interim Analysis of a French Multicenter Compassi...
ALLY-3 Design Objective SVR
ALLY-3 Design Objective SVR
by mitsue-stanley
12. (HCV RNA < 25 IU/ml), . with. 95% CI. DC...
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...
SIRIUS
SIRIUS
by tawny-fly
Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...
Virological characterization of patients with CHC and failure to a
Virological characterization of patients with CHC and failure to a
by isabella2
glecaprevir. /. pibrentasvir. or . voxilaprevir. ...
Are Pan-Genotypic Therapies Ready for Prime Time?
Are Pan-Genotypic Therapies Ready for Prime Time?
by lois-ondreau
3. Rd. International . HIV/Hepatitis . Coinfecti...
NIAID ERADICATE
NIAID ERADICATE
by tatiana-dople
Open-label. W12. ≥ 18 years. Chronic HCV infect...
Design Sofosbuvir / velpatasvir
Design Sofosbuvir / velpatasvir
by fullyshro
for 12 weeks in liver transplant recipients with g...
Randomisation 2 : 1 Open-label
Randomisation 2 : 1 Open-label
by stefany-barnette
≥ 18 years. HCV genotype 3. Treatment-naïve ....